A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218
Completed · Phase 1
Conditions studied: Renal Impairment
In brief
The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal renal function and participants with varying degrees of renal dysfunction who are otherwise medically stable
Key facts
- Study ID
- NCT05844228
- Run by
- Vir Biotechnology, Inc.
- People needed
- 28
- Starts
- 2023-06-01
- Expected to finish
- 2025-04-21
- Last updated by the study team
- 2025-06-13
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.
Where it is running
- Inland Empire Clinical Trials — Rialto, California, United States
- Floridian Clinical Research — Miami Lakes, Florida, United States
- Orlando Clinical Research Center — Orlando, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.